In vitro cultivation of the human microsporidium Vittaforma corneae: development and effect of albendazole
Jazyk angličtina Země Česko Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
Grantová podpora
Wellcome Trust - United Kingdom
PubMed
8774778
Knihovny.cz E-zdroje
- MeSH
- albendazol farmakologie MeSH
- anthelmintika farmakologie MeSH
- buněčné linie MeSH
- fibroblasty MeSH
- ledviny MeSH
- lidé MeSH
- Microsporida účinky léků růst a vývoj ultrastruktura MeSH
- Nosema účinky léků růst a vývoj ultrastruktura MeSH
- plíce embryologie MeSH
- psi MeSH
- spory MeSH
- Xenopus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- psi MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- albendazol MeSH
- anthelmintika MeSH
When in vitro growth of Vittaforma corneae was tested using MDCK, MRC-5, XEN, L-929 and FHM cell lines, propagation occurred only in MDCK, MRC-5 and XEN cells. The intervals required for the various stages of the life cycle to develop were the same in all the cell lines tested. The MDCK cell line was selected to support the growth of V. corneae in vitro and provide the system for in vitro testing of drugs. The weekly output of V. corneae spores from the MDCK cell monolayer was monitored over a 61-week period during which there were fluctuations but no definite increase or decrease in output. Albendazole at 2.1 or 4.2 micrograms/ml in MEM was tested against V. corneae in MDCK cell monolayers and showed antimicrosporidial activity. The percentage of infected cells was reduced in the presence of the drug and there were ultrastructural abnormalities in all stages of the life cycle. The drug prevents parasite division.
